1986 Volume 47 Issue 12 Pages 1568-1573
The usefulness of a new tumor marker, KM01, the monoclonal antibody of which, for established cells of human colonic carcinoma, detects the presence of tumor, was determined using both clinical procedures and an experimental tumor line, and was compared with those of CA19-9, CEA and IAP. The measurement of KM01-RPHA was found to be convenient, showing positive rates of 80.0% and 44.0% in cases of pancreatic carcinoma and gastric cancer, respectively, and furthermore showing a high positive rate of 80.0% in cases of relapsed gastric and colonic carcinomas. Consequently KM01 seems to be useful as a tumor marker. The results of measurements with KM01 and CA19-9 were consistent and the correlation between antibody values of KM-01-RPHA and measurements with CA19-9 was high. The false-positive rate for KM01 was higher than that for CA19-9, suggesting that KM01-RPHA contains antigenic determinants similar to those of CA19-9, facilitating measurement over a wider range than in the case of CA19-9. The antibody value of KM01-RPHA was correlated with CEA but not with IAP. In culutured sera of three kinds of established cancer cells, release of KM01 was found. Among these KUM MK-2 was transplanted into nude mice, and release of KM01 into the sera of the nude mice was initially recognized.
